Purifying Antibodies May 3 - 4

» 1:40 KEYNOTE PRESENTATION 

Novel Molecules, Novel Purification Processes?

David J. Roush, Ph.D., Senior Investigator, BioProcess, Protein Purification Development, Merck Research Labs (biography)

Advances in cell culture/fermentation development and a plethora of options for expression systems have eliminated most of the upstream productivity bottleneck. The current challenge is to globally optimize the productivity of the entire process while maintaining product quality and cost targets and maximizing facility utilization. The increased diversity of molecular types and truncated development times require a reassessment of a platform purification approach and a collaborative, strategic evaluation of new purification modalities.

» 2:10 Featured Presentation 

Streamlining Processes and Process Development with High-Throughput Screening and Analytical Tools

Joey M. Studts, Ph.D., Director, Protein Science, Boehringer Ingelheim Pharma GmbH & Co. (biography)

To efficiently integrate technologies, the Protein Science Department has developed the BI-PurEx Strategy. This strategy ensures a rapid, effective and flexible development timeline and an efficient process to meet the demands at any stage in product development, from clinics to market. This presentation will demonstrate how the integration of data from high-throughput biophysical assays and automated screening is used to develop critical process knowledge and a fast track to success without impacting the critical path to clinical trial material.

4:00-5:00 Problem Solving Breakout Discussions

Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.

Possible Impact of Molecular Modeling on Antibody Purification Processes

Moderator:  Carlo Cavallotti, Ph.D., Associate Professor, Dipartimento di Chimica, Materialied Ingegneria Chimica “G. Natta,” Politecnico di Milano

• What is the best way to use molecular modeling to improve the performances of separation processes?
• How can molecular modeling predictions be validated in order to establish an ‘experiment-model-prediction’ virtuous cycle?
• Which are the aspects of antibody purification that would benefit mostly from a molecular level understating of the involved phenomena?

Jason and the Argonauts MMXII-The Quest for the Golden Antibody

Moderator:  Dan L. Crimmins, Ph.D., Senior Scientist, Pathology & Immunology, Lab & Genomic Medicine, Washington University School of Medicine

• Commercial Ab's are a "hit or miss" proposition.
• Considerable time and resource are wasted.
• How can investigators change this?
• Require greater validation from vendors.
• Availability of Ab specific, detailed application protocols.
• Potentially  a "win-win" business proposition.

How Pure is Pure?

Moderator:  David O’Connell, Ph.D., Senior Scientist, School of Medicine, University College Dublin

• What are acceptable limits of purity
• Rapid methods for establishing level of purity
• The need for high sensitivity assessment e.g., MS based analysis
• Experiences of different tag systems